Fig. 1From: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysisFlowchart of the study selection process. RCT, randomized controlled trialBack to article page
